(RTTNews) – Clinical-stage biopharmaceutical company Biohaven Ltd. (BHVN) Tuesday announced positive biomarker data from the Phase 1 electroencephalogram (EEG) biomarker study of its lead asset BHV-7000, proposed for the treatment of epilepsy.
Examination of EEG in healthy subjects administered single doses of BHV-7000 confirmed central nervous system (CNS) activity consistent with effects observed with other antiseizure medications, the company said.
These results were presented at an off-site meeting held during the International Epilepsy Conference 2023 in Dublin, Ireland.
Biohaven said it plans to initiate Phase 3 study of BHV-7000 in focal epilepsy this year.
Comments are closed.